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Abstract
Medication adherence is highly predictive of health outcomes across chronic conditions, 
particularly HIV/AIDS. Depression is consistently associated with worse adherence, yet few 
studies have sought to understand how depression relates to adherence. This study tested three 
components of behavioral depression theory—goal-directed activation, positive reinforcement, 
and environmental punishment—as potential indirect effects in the relation between depressive 
symptoms and medication nonadherence among low-income, predominantly African American 
substance users (n = 83). Medication nonadherence was assessed as frequency of doses missed 
across common reasons for nonadherence. Non-parametric bootstrapping was used to evaluate the 
indirect effects. Of the three intermediary variables, there was only an indirect effect of 
environmental punishment; depressive symptoms were associated with greater nonadherence 
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through greater environmental punishment. Goal-directed activation and positive reinforcement 
were unrelated to adherence. Findings suggest the importance of environmental punishment in the 
relation between depression and medication adherence and may inform future intervention efforts 
for this population.
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Introduction
Medication adherence is of utmost importance across numerous chronic medical conditions, 
and arguably most impactful on health outcomes in HIV/AIDS. Indeed, anti-retroviral 
therapy (ART) for the treatment of HIV/AIDS has substantially improved clinical outcomes 
(Crum et al., 2006). However, positive health outcomes require consistent ART use and high 
levels of ART adherence (García et al., 2002). For this reason, there is great value in 
understanding the factors associated with suboptimal adherence.
One of the most prevalent and powerful predictors of nonadherence across chronic medical 
conditions is depression (DiMatteo et al., 2000). In HIV, recent meta-analyses and reviews 
of the relationship between depression and ART adherence (n = 42,366; 111 studies) have 
been definitive in the effects of depression on adherence (Gonzalez et al., 2011; Uthman et 
al., 2014). These meta-analyses included studies conducted in both higher-income areas 
(e.g., US, countries in Western Europe, Canada, Hong Kong, Australia) and lower-income 
countries (e.g., Ethiopia, South Africa, India, Peru, Uganda, Nigeria, Kenya). Depression as 
a barrier to adherence among HIV-positive individuals has received significant empirical 
and clinical attention given (1) its high prevalence among individuals with HIV/AIDS (e.g., 
Asch et al., 2003; Bing et al., 2001) and (2) the link between depression and later HIV 
disease progression (Gore-Felton & Koopman, 2008; Leserman et al., 2002). Among urban, 
low-income substance users living with HIV, rates of major depression have been shown to 
reach 72 % (Berger-Greenstein et al., 2007). Even at sub-threshold levels, depressive 
symptoms have a strong relationship with nonadherence; in a sample of substance users in 
methadone maintenance, a one-point increase in clinician-rated depressive symptoms (on the 
seven-point depression Clinical Global Impression Scale) was associated with a 75 % 
increase in the odds of ART nonadherence. Thus, even a moderate depression rating 
according to this scale would indicate almost a fivefold increase in the odds of nonadherence 
as compared to when no depressive symptoms are present (Gonzalez et al., 2011).
Despite the focus on depression as a reliable and powerful factor associated with medication 
nonadherence across chronic health conditions and among substance users living with HIV 
specifically, few studies have examined factors that may account for the relation between 
depression and medication nonadherence. It is particularly important to develop behavioral 
interventions to address improvements in medication adherence in populations most affected 
by depression, such as urban, low-income substance users (Berger-Greenstein et al., 2007). 
As such, the current study drew from longstanding behavioral theories of depression 
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(Lewinsohn, 1974; Ferster, 1973) to identify key components that have particular relevance 
to medication adherence. These theories suggest that depression is characterized by: (1) 
lower levels of goal-directed activation (i.e., individuals engage in fewer pleasant activities 
or activities of mastery; Lewinsohn & Graf, 1973; Lewinsohn & Libet, 1972); (2) less 
positive reinforcement available in one’s environment (i.e., due to fewer social supports, 
other resources); and (3) greater experience of perceived punishment in one’s environment 
(i.e., greater experience of negative or aversive consequences).
Although these constructs have not been tested in relation to medication nonadherence 
specifically, there is evidence from the medication adherence literature suggesting the 
relevance of these constructs to adherence, and in particular to the relation between 
depression and adherence. First, regarding goal-directed activation, previous research has 
demonstrated that “patterns of regular behaviors and activities” (Wagner & Ryan, 2004), 
including changes in daily routine and ability to fit a regimen into a daily routine, have 
consistently been identified as important factors related to medication adherence, including 
ART, other forms of medication, and even placebos (Chesney et al., 2000; Gifford et al., 
2000; Roberts, 2000; Wagner & Ryan, 2004). Second, various lines of evidence suggest that 
positive reinforcement in one’s environment may be important to inspire continued 
motivation for self-care behaviors (Berger-Greenstein et al., 2007; Holzemer et al., 1999; 
Ryan & Wagner, 2003). Third, regarding environmental punishment, perception of being 
exposed to punishing or aversive experiences is associated with the belief that behavioral 
choices will not lead to subsequent reinforcement (Hiroto, 1974; Rotter, 1966), such as 
positive health benefits of adherence. Similar constructs (e.g., external locus of control; 
Rotter, 1975) have shown that such beliefs are associated with poor adherence across 
chronic conditions, such as diabetes (Schlenk & Hart, 1984), hypertension (Stanton, 1987), 
and HIV (Aversa & Kimberlin, 1996; Evans et al., 2000). Finally, focusing on behavioral 
factors has high potential for applicability to medication nonadherence, given that the most 
commonly cited reasons for medication nonadherence are behavioral (e.g., Chesney, 2003; 
Palmer et al., 2003).
In sum, although the specific components of behavioral theories of depression have not been 
tested in relation to medication adherence, numerous lines of evidence suggest their 
relevance. As such, in the current study we tested the role of each of these three components 
as indirect effects in the relation between depressive symptoms and medication 
nonadherence. We hypothesized that lower levels of goal-directed activation, lower levels of 
positive reinforcement, and higher levels of environmental punishment would each be 
related to greater medication nonadherence, and further, that each would be a significant 
indirect effect in the relation between depressive symptoms and medication adherence.
Methods
Participants and procedure
Low-income HIV-positive substance users were recruited given the high rates of depressive 
symptoms and medication nonadherence commonly identified in this population (Berger-
Greenstein et al., 2007). Participants were recruited from a large, urban residential substance 
abuse treatment center in the Northeast United States. Patients were referred by government 
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agencies or mandated to treatment by the court system. Patients were required to have 
completed full detoxification and have a negative urine drug screen upon admission to the 
treatment facility. During this time period, all patients in the facility received a standard 
intake interview that included an assessment of medical history and daily medication use, 
which was verified with center records and used to determine study eligibility.
Patients were eligible if they were HIV-positive and were prescribed a medication regimen 
that required daily dosing. Patients were excluded if they were not prescribed any daily 
medication, which was necessary to assess medication adherence. Eligible patients were 
provided detailed information about study procedures and those interested provided 
informed consent. The importance of maintaining patient confidentiality and privacy was 
stressed throughout the study screening session. Treatment center staff members were not 
made aware of patients’ study participation or refusal, and participation in the study did not 
affect patients’ status in treatment. All structured clinical interviews and assessments were 
conducted by trained post-baccalaureate and pre-doctoral clinical psychology graduate 
students (six total). All study procedures were approved by the University Institutional 
Review Board.
Ninety-two participants were approached for the current study. Three declined participation 
(3.3 %), and six were excluded because they were not prescribed any daily medication 
regimen (6.5 %). Of the final sample (n = 83), 95.2 % were African American, 71.1 % 
heterosexual, 45.8 % female, and the mean age was 45.20 (SD 7.89). Patients were in 
substance abuse treatment for a mean of 13.76 days (SD 8.47) at the time of the study 
assessment.
Assessment measures
Demographics form assessed age, race/ethnicity, sexual orientation, education level, marital 
status, employment status, and annual household income.
The Structured Clinical Interview for the DSM-IV (SCID-IV; First & Gibbon, 2004) was 
used to assess current DSM-IV Axis-I and II psychopathology (past month for mood 
disorders and anxiety disorders, past year for substance use disorders) and administered by a 
trained clinician.
The Hamilton Depression Rating Scale—7 item version (HAMD-7; Maier & Phillip, 1985) 
was used to assess depressive symptoms. The HAMD-7 is a clinician-rated measure of 
severity of depressive symptoms. Clinicians rate each of the 7 items on a scale of 0–4 with 
higher scores indicating increased depression severity. Previous research has shown that the 
measure has strong internal consistency (α = 0.84) and excellent convergent validity with 
the Montgomery-Asberg Depression Rating Scale (MADRS) (r = .90; McIntyre et al., 
2005).
The Behavioral Activation for Depression Scale (BADS; Kanter et al., 2007) was used to 
measure goal-directed activation. The BADS is a 25-item self-report measure of the 
frequency of activation as outlined in behavioral theories of depression, with one subscale 
specifically (“activation”) assessing goal-directed activity level. Example items include “I 
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engaged in a wide and diverse array of activities” and “I did something that was hard to do 
but it was worth it”). Higher scores indicate greater activation. The BADS has been 
demonstrated to have strong internal consistency (α = 0.92) and good test–retest reliability 
(r = .74) in depressed and non-depressed samples (Kanter et al., 2007, 2009). Internal 
consistency for the activation subscale was good in this sample (α = 0.80).
The Reward Probability Index (RPI; Carvalho et al., 2011) was used to measure positive 
reinforcement and environmental punishment and was developed specifically in line with 
Lewinsohn’s model of depression. The RPI has 20 items and a two-facture structure, which 
includes “Reward Probability” and “Environmental Suppressors.” The Reward Probability 
subscale consists of 11 items related to the number of potential reinforcers and an 
individual’s ability to obtain reinforcement through instrumental behaviors. Example items 
in this subscale include “It is easy to find good ways to spend my time” and “I have the 
abilities to obtain pleasure in life.” Higher scores indicate greater probability of reward in 
the environment. The Environmental Suppressors subscale includes 9 items that assess the 
presence of aversive stimuli in the environment. Example items include “I have had many 
unpleasant experiences” and “It seems like bad things always happen to me.” Items in this 
subscale are reverse scored, and higher scores on this subscale indicate lower levels of 
environmental punishment. The RPI has been demonstrated to have strong internal 
consistency (α = 0.90) and test–retest reliability (r = .69). In the current sample, internal 
consistency for the two subscales ranged from acceptable to good (Environmental 
Suppressors: α = 0.70; Reward Probability: α = 0.86).
The ACTG Adherence to Antiretroviral Medication Questionnaire (Chesney et al., 2000) 
was used to assess self-reported medication adherence. Specifically, medication adherence 
was assessed for all daily medications prescribed (ART, psychotropic medications, 
cardiovascular medications, diabetes medications, anticonvulsants, and hormones). 
Participants provide a list of all daily medications prescribed in the 4 days prior to the study 
assessment and the number of doses taken. Ratios were calculated of the number of doses 
missed versus doses prescribed over the past 4 days for all daily medications.
The ACTG was also used to assess frequency of doses missed across a range of reasons as a 
second indicator of self-reported nonadherence. Querying for reasons for nonadherence has 
been recommended as a way to minimize potential biases of self-report when assessing 
adherence, including inaccurate recall and social desirability (Simoni et al., 2006), and this 
measure has been used previously as a main adherence outcome (O’Cleirigh et al., 2007; 
DiIorio et al., 2009). Participants were presented a list of 14 reasons why people may ever 
miss taking their medications and were asked “how often have you missed taking your 
medications because you…” for each reason. Participants rate responses on a four-point 
scale (never, rarely, sometimes, often) to indicate the frequency of nonadherence due to each 
of the 14 reasons. The responses were summed to create a total score of frequency of doses 
missed across commonly endorsed reasons for medication nonadherence, which follows 
prior research (O’Cleirigh et al., 2007; DiIorio et al., 2009). Higher scores indicating greater 
frequency of doses missed across reasons for non-adherence. A previous factor analysis of 
the 14-item ACTG reasons for nonadherence questionnaire identified five items that loaded 
together on a single factor (i.e., “were away from home” “were busy with other things”; 
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“simply forgot”; “had a change in daily routine; and “fell asleep/slept through dose time”), 
which was conceptualized as unintentional “logistical problems” related to nonadherence (α 
= 0.86 for factor). All analyses were conducted examining nonadherence across (1) all 
reasons and (2) “logistical/unintentional” reasons separately. Internal consistency for the 
nonadherence reasons subscale was excellent α = 0.90.
CD4 count was used as a biological indicator of health status given its relevance to 
depression in prior trials (Burack et al., 1993; Ickovics et al., 2001; Leserman, 2008). This 
was obtained from participants’ medical records of the most recent blood work appointment 
within a 90-day window from the assessment (60 days prior, 30 days after). Participants also 
self-reported years since HIV diagnosis and basic health care-related characteristics (i.e., 
whether they had a primary care physician [PCP] and a health insurance plan). All health 
status measures were considered as potential covariates.
Statistical analyses
We first conducted a correlation matrix to examine the relation among study variables (see 
Table 2). Next, we utilized non-parametric bootstrapping to examine the indirect effects of 
goal-directed activation, positive reinforcement, and environmental punishment separately 
in all three aims. Frequency of doses missed across all reasons for nonadherence was the 
primary dependent variable. We also examined whether any results changed when including 
the logistical/unintentional reasons factor as the outcome variable. Non-parametric 
bootstrapping is recommended for small samples, because there are no assumptions about 
the shape of the sampling distribution of the indirect effect (Preacher & Hayes, 2004). 
Bootstrapping is based on resampling with replacement, which is done many times to 
generate an empirical approximation of the sampling distribution of the indirect effect 
(Hayes, 2009). Non-parametric bootstrapping analyses conducted were based upon 5,000 
bootstrapped samples (recommended by Hayes, 2009), and we used the INDIRECT SPSS 
Macro developed by Preacher and Hayes (2008). Indirect effects are significant if the 95 % 
bias-corrected or percentile-based confidence intervals (CIs) for the indirect effect do not 
include 0 (Preacher & Hayes, 2004, 2008). Covariates were selected based upon their 
relation to the dependent variable (Tabachnik & Fidell, 2007), including all variables listed 
in Table 1 as well as medication status (class of medication taken, ART status).
Results
Medication characteristics
Participants were taking an average of 5.82 pills per day (SD 3.48). 68.7 % (n = 57) of the 
current sample was taking ART, 38.6 % of the sample was taking cardiovascular drugs, 41.0 
% antidepressant medication, 15.7 % anticonvulsant medication, 12.0 % diabetes 
medication, and 3.6 % daily hormones. Participants on ART were taking an average of 3.16 
antiretroviral pills per day (SD 1.74). See Table 1 for additional demographic and clinical 
information for the total sample and by ART status. Mean adherence rates ranged from 
94.46 to 97.72 % in the past 4 days; daily medication adherence rates were 97.72 % 
yesterday, 94.46 % 2 days ago, 97.02 % 3 days ago, and 96.85 % 4 days ago. There was 
little variability in rates of nonadherence over the past 4 days, and more specifically a 
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ceiling in rates of nonadherence was present. All adherence ratios were highly skewed 
(skewness statistics<−4.5 for all ratios), which was not improved following transformations. 
Thus it was not possible to use these ratios in analyses. However, there was greater 
variability in our second indicator of adherence: frequency of doses missed across reasons 
for nonadherence. Frequency of doses missed across reasons for nonadherence was in the 
normal range for skew and kurtosis and was not transformed. Responses ranged from 0 to 
36, and the mean of the total score in the current sample was 12.01 (SD 9.32).
Correlations between variables
Table 2 shows the correlations amongst depressive symptoms, goal-directed activation, 
positive reinforcement, environmental punishment, and medication nonadherence 
(frequency of doses missed across all reasons for nonadherence and logistical/unintentional 
reasons only). Higher depressive symptoms (r = .30, p < .01) and greater environmental 
punishment (−0.40; p < .01) were significantly associated with greater frequency of doses 
missed across all reasons for nonadherence. Depressive symptoms unrelated to frequency of 
doses missed when reasons were restricted to only those that were logistical/unintentional.
Identification of covariates
All variables listed in Table 1 were tested in relation to the primary dependent variable 
(frequency of doses missed across reasons endorsed for nonadherence). The only variables 
significantly related to greater frequency of doses missed across reasons were sexual 
orientation and crack/cocaine dependence; individuals who identified as homosexual or 
bisexual reported significantly greater frequency of doses missed across reasons compared 
to heterosexual individuals (t(74) = 3.18, p < .005), and individuals with crack/cocaine 
dependence also reported significantly greater frequency of doses missed across reasons 
compared to individuals without crack/cocaine dependence (t(71) = −3.01 p < .005). All 
other relations were non-significant (all p’s > 0.15). We examined type of medication being 
taken and ART status as potential covariates; however, neither was significantly correlated 
with the dependent variable (all p’s > 0.6). Given the majority of the sample was African 
American, we also ran all analyses only including African American individuals (n = 79), 
and this did not affect the significance or parameters of any results reported below.
Indirect effects
Goal-directed activation—We first tested the indirect effect of goal-directed activation 
in the relation between depressive symptoms and medication nonadherence (frequency of 
doses missed across all reasons for nonadherence). Results indicated that there was not a 
significant indirect effect of goal-directed activation [IE = −0.004, SE = 0.08; Bias-
Corrected 95 %CI −0.23, 0.08]. Next, we tested the indirect effect of goal-directed 
activation in the relation between depressive symptoms and unintentional medication 
nonadherence (frequency of doses missed across logistical/unintentional reasons for 
nonadherence). Results indicated that there was not a significant indirect effect of goal-
directed activation in this relationship [IE = −0.02, SE = 0.04; Bias-Corrected 95 %CI −0.13, 
0.03].
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Positive reinforcement—Second, we tested the indirect effect of positive reinforcement 
in the relation between depressive symptoms and medication nonadherence (frequency of 
doses missed across all reasons for nonadherence). Results indicated that there was not a 
significant indirect effect of positive reinforcement [IE = 0.05, SE = 0.11; Bias-Corrected 95 
%CI −0.13, 0.33]. Next, we tested the indirect effect of positive reinforcement in the relation 
between depressive symptoms and unintentional medication nonadherence (frequency of 
doses missed across logistical/unintentional reasons for nonadherence). Results indicated 
that there was not a significant indirect effect of positive reinforcement in this relationship 
[IE = 0.002, SE = 0.05; Bias-Corrected 95 %CI −0.08, 0.11].
Environmental punishment—Finally, we tested the indirect effect of environmental 
punishment in the relation between depressive symptoms and medication nonadherence 
(frequency of doses missed across all reasons for nonadherence). Results indicated that there 
was a significant indirect effect of environmental punishment [IE = 0.17, SE = 0.12; Bias-
Corrected 95 %CI 0.005, 0.52]. Specifically, individuals with higher levels of clinician-rated 
depressive symptoms had greater experiences of environmental punishment, and through 
higher levels of environmental punishment, reported greater frequency of missed medication 
doses across reasons for medication nonadherence (see Fig. 1 for a depiction of these 
results). Next, we tested the indirect effect of environmental punishment in the relation 
between depressive symptoms and unintentional medication nonadherence (frequency of 
doses missed across logistical/unintentional reasons for nonadherence). Results indicated 
that there was not a significant indirect effect of environmental punishment when the 
dependent variable was restricted to unintentional/logistical reasons for nonadherence [IE = 
0.05, SE = 0.05; Bias-Corrected 95 %CI −0.02, 0.20].
Discussion
The current study sought to apply behavioral theories of depression (Ferster, 1973; 
Lewinsohn, 1974) to inform the understanding of how depression may relate to medication 
nonadherence. Related lines of research from the adherence literature suggested that each of 
the three components of behavioral theories of depression—goal directed activation, positive 
reinforcement, and environmental punishment—may be relevant to medication 
nonadherence, although this had not been explicitly tested. Of the three key components of 
behavioral theories of depression, only environmental punishment was significantly related 
to medication nonadherence when assessed as the frequency of doses missed across all 
commonly endorsed reasons for medication nonadherence. Goal-directed activation and 
positive reinforcement were unrelated to medication non-adherence.
The finding that environmental punishment may play an important role in the relation 
between depressive symptoms and nonadherence fits with the theoretical framework of 
external locus of control of reinforcement, particularly as applied to health behavior 
(Wallston et al., 1978). It has been suggested that perceptions of punishment and external 
locus of control are overlapping constructs (Hiroto, 1974; Rotter, 1966), and as such, 
although we did not assess external locus of control directly, it may be useful to draw from 
this well-established framework to interpret the current study findings. The locus of control 
theoretical framework suggests that the degree to which individuals expect that a particular 
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outcome is contingent on their own behavior or personal characteristics is strongly related to 
the likelihood of engaging in that behavior (Rotter, 1975). Individuals with an external locus 
of control are less likely to perceive direct benefits from healthy behavior and rather are 
more likely to report aversive consequences (i.e., environmental punishment) as a result of 
attempting healthy behavior and a lack of control over managing their health condition 
(Rotter, 1966; Wallston et al., 1978). The current study’s findings fit with previous research 
demonstrating that an external locus of control has been strongly implicated in depression, 
in particular in relation to symptoms of depression related to avolition (Benassi et al., 1988), 
substance use (Newcomb & Harlow, 1986), and persistence with self-care across numerous 
chronic conditions, such as diabetes (Schlenk & Hart, 1984), hypertension (Stanton, 1987), 
as well as HIV/AIDS (Aversa & Kimberlin, 1996; Evans et al., 2000).
Environmental punishment was only a significant indirect effect in the model when 
medication adherence was examined across all reasons for nonadherence. When assessed 
using a single factor—“unintentional/logistical” reasons for nonadherence—environmental 
punishment no longer was a significant indirect effect. Depressive symptoms were not 
significantly associated with frequency of doses missed for unintentional reasons. This may 
suggest that environmental punishment plays a stronger role in explaining the relationship 
between depressive symptoms and medication nonadherence when nonadherence is largely 
due to intentional reasons for missed doses (i.e., “wanted to avoid side effects,” “felt like the 
drug was toxic/harmful”). Individuals with depression who are more likely to anticipate 
environmental punishment may have reduced motivation to take medication and/or greater 
perceived negative consequences of medication use. The findings also suggest that 
depression may be more closely related nonadherence when missed doses are intentional as 
opposed to unintentional or more reflective of logistical reasons (e.g., simply forgetting, 
sleeping through dose time). However, this is contrary to recent evidence suggesting that 
depressive symptoms disrupt adherence through disruptions in lifestyle structure and routine 
(Magidson et al., 2013, 2014). There has been prior research on the differential aspects of 
depression in relation to medication adherence (e.g., Wagner et al., 2011), and greater 
empirical attention is needed to understand how depression may differentially impact 
unintentional versus intentional patterns of medication adherence.
Regarding the non-significant relations of goal-directed activation and positive 
reinforcement with frequency of doses missed across commonly endorsed reasons for 
medication nonadherence, it may be that these constructs are not as strongly related to 
medication nonadherence compared to environmental punishment. Alternatively, this may 
also reflect the setting in which the current study was conducted—a controlled environment 
with very little variability or flexibility regarding one’s schedule and few ways to obtain 
reinforcement from one’s environment—which may have made activation and 
reinforcement in one’s environment less relevant to medication adherence. In future work, 
recruiting participants from a community setting or an outpatient center where individuals 
have greater control over their schedule and opportunities for obtaining reinforcement may 
be useful.
Additionally, it is interesting to note that of the potential covariates, only crack cocaine 
dependence diagnosis in the past year and sexual orientation (self-identified homosexual or 
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bisexual) were related to a greater frequency of doses missed across reasons for 
nonadherence. Recent crack cocaine use has been shown to be associated with suboptimal 
adherence to ART (Eldred et al., 1998; Sharpe et al., 2004), with adherence concerns for 
other types of medications among HIV-positive individuals (i.e., by providers in HIV 
patients’ medical records; Ingersoll, 2004), and with reduced insulin adherence in diabetes 
care (Warner et al., 1998). The finding that sexual orientation was associated with 
medication nonadherence in this predominantly African American sample fits with prior 
research that has pointed to high risk for poor HIV-related self care among African 
American men who have sex with men (MSM) (Bogart et al., 2010; Malebranche et al., 
2004).
The current study recruited specifically low-income, HIV-positive substance users at high 
risk for poor HIV outcomes (i.e., resulting from ART nonadherence or not being on ART; 
Chander et al., 2009). Indeed, we found that almost one-third of our sample recruited was 
not taking ART, supporting the notion that this is a sample at high risk for poor HIV 
outcomes. Including more HIV-positive individuals not on ART in adherence research is 
important to understand unique barriers towards ART uptake facing this group. HIV-
positive individuals often face other comorbid chronic conditions such as diabetes, Hepatitis 
C, hypertension, and arthritis; a study of patients seeking treatment at HIV clinics revealed 
89 % had comorbid conditions, with a mean of 2.4 comorbid conditions per patient, and 81 
% taking medications for conditions other than HIV infection (Shah et al., 2002). This is 
consistent with our sample, with almost 40 % of the sample taking cardiovascular 
medications and approximately the same percentage taking antidepressant medication, with 
an overall mean pill count of almost six pills per day. Adherence to multiple other forms of 
medication is likely challenging, and in particular, low-income, African American HIV-
positive individuals have been shown to be least likely to be adherent to other forms of 
medication (i.e., to TB medication; Pablos-Méndez et al., 1997). This clearly underscores 
the importance of also understanding factors relevant to adherence to medications other than 
ART in this population.
One primary limitation of the current study is the single assessment time point, and as such 
causation or directionality cannot be inferred from findings. Although a longitudinal design 
is necessary for testing true mediation and causality (Maxwell & Cole, 2007), cross-
sectional designs can still provide insight regarding potential indirect effects, which begin to 
address functional relations and may spur future empirical questions to be tested in larger 
longitudinal designs. Other limitations relate to the assessment of adherence. Our priority in 
recruiting a group at highest risk for poor outcomes also forced us to forgo precision in our 
adherence assessment (i.e., rather than only focusing on individuals on ART). Although not 
empirically supported in this sample, it is possible that actual rates of adherence differ across 
different medical conditions and medication types, which may also hold true across different 
classes of ART given differing dosing instructions and side effect profiles (e.g., Airoldi et 
al., 2010). It is also very likely that adherence to these other forms of medication (e.g., 
antidepressants), may have a direct effect on ART adherence (Horberg et al., 2008; Walkup 
et al., 2008). Although we were not powered in the current sample to run the primary 
analyses comparing individuals on ART versus not (Fritz & MacKinnon, 2007), this would 
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be an important direction for future work using larger sample sizes to examine whether these 
results differ when comparing adherence to ART versus other medications.
Given how high rates of self-reported adherence were in the past 4 days—reaching almost 
100 %—there was not sufficient variability in this measure to meaningfully analyze. The 
high rates of adherence in the past 4 days may reflect typical inflation of self-reported 
adherence behavior when asked to report on missed doses directly (Kalichman et al., 2009; 
Liu et al., 2001; Simoni et al., 2006) or actual high adherence rates common in the context 
of a controlled, substance abuse treatment setting (Hicks et al., 2007). This is in line with 
recent reviews that have shown HIV-positive substance users adhere to ART at comparable 
rates to HIV-positive individuals who do not use drugs (Malta et al., 2008) and that 
adherence interventions can be effective to improve adherence in the short-term for HIV-
positive substance users (Binford et al., 2012).
Although not necessarily a perfect proxy for actual adherence behavior, querying for reasons 
for nonadherence has been suggested to be an effective strategy to minimize social 
desirability biases and other inaccuracies of self-reported adherence (Simoni et al., 2006), 
yet there are some significant limitations of this measure. It is unclear whether a greater 
frequency of doses missed across commonly endorsed reasons for nonadherence reflects 
actual missed doses. It may be that some individuals perceive greater barriers to adherence 
and report nonadherence across a range of reasons, whereas other individuals may 
consistently miss more doses but for a single reason. Although difficult in a controlled 
environment with little privacy, electronic pill caps (for ART as well as other medications) 
would have been a potentially more accurate, objective measure of adherence. Future studies 
must examine the accuracy of assessing reasons endorsed for nonadherence as a measure of 
missed doses by comparing it to objective measures of adherence. Finally, generalizing 
these findings to global resource-limited settings should be done with caution; although 
findings from recent meta-analyses suggest the relationship between depression and 
adherence is consistent across low- and high-income countries (Gonzalez, Batchelder et al., 
2011; Uthman et al., 2014), and that there are not significant differences in rates of 
depression based upon country income level (Uthman et al., 2014).
Conclusions
Considered within the context of the limitations noted above, the findings do have important 
potential clinical implications. The identification of a potentially modifiable factor that plays 
an important role in the relation between depression and medication adherence may lend 
itself to future intervention development efforts. Findings point to the unique role of 
environmental punishment in the relation between depression and medication adherence. If 
findings continue to replicate, this may suggest adapting existing interventions for 
depression and adherence among substance users to focus more exclusively on reducing 
environmental punishment—or perceptions of punishment—and the impact environmental 
punishment may have on one’s perceived self-efficacy to adhere to medication regimens. 
Existing cognitive behavioral interventions for improving depressive symptoms and 
medication adherence among substance users with HIV/AIDS (Daughters et al., 2010; 
Magidson et al., 2013, 2014; Safren et al., 2012) may incorporate strategies to more directly 
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address perceptions or experiences of environmental punishment that may interfere with 
adherence; this may assist with anticipating and normalizing the potential punishing 
experiences one may encounter when taking ART (side effects, stigma, etc.). These findings 
are a first step in improving the understanding of how depression may relate to medication 
nonadherence and the role environmental punishment plays in this relation among HIV-
positive, predominantly African American substance users. Along with future replications 
and extensions of this work, these findings may spur efforts for continued refinement of 
clinical interventions for this population.
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Indirect effect of environmental punishment in the relation between depressive symptoms 
and frequency of missed doses across all reasons for medication nonadherence. *<0.05; 
**<0.01. Bootstrapping results: Indirect Effect (IE) = 0.17, SE = 0.12; Bias-corrected 95 % 
CI 0.005, 0.52. Depressive symptoms Hamilton Depression Rating Scale (higher scores = 
greater depressive symptoms); environmental punishment Reward Probability Index (higher 
scores = lower punishment); medication adherence AIDS Clinical Trials Group (ACTG) 
assessment of frequency of doses missed across all reasons for nonadherence (higher scores 
= greater nonadherence)
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